Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACIUNASDAQ:AVTENASDAQ:SCPHNASDAQ:SGTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACIUAC Immune$1.93-7.0%$1.67$1.43▼$4.83$193.79M1.57153,072 shs83,903 shsAVTEAerovate Therapeutics$7.03-0.4%$36.88$43.75▼$884.98$203.77M0.9519,176 shs297,915 shsSCPHscPharmaceuticals$3.97-0.9%$2.95$1.94▼$5.65$209.32M0.36367,705 shs128,925 shsSGTXSigilon Therapeutics$22.47$22.02$3.77▼$28.00$56.40M4.1262,902 shsN/A10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACIUAC Immune-2.36%+19.65%+31.85%-9.61%-55.39%AVTEAerovate Therapeutics-0.42%-2.50%-18.07%-91.87%-99.13%SCPHscPharmaceuticals-1.96%-2.68%+72.41%+32.01%-0.99%SGTXSigilon Therapeutics0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACIUAC Immune3.003 of 5 stars3.53.00.00.03.30.81.3AVTEAerovate Therapeutics2.0142 of 5 stars3.00.00.00.03.11.70.6SCPHscPharmaceuticals4.4651 of 5 stars3.54.00.04.23.51.70.6SGTXSigilon TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACIUAC Immune 3.00Buy$12.00523.38% UpsideAVTEAerovate Therapeutics 2.00Hold$78.751,020.20% UpsideSCPHscPharmaceuticals 3.00Buy$14.00253.09% UpsideSGTXSigilon Therapeutics 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest SGTX, SCPH, AVTE, and ACIU Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/1/2025ACIUAC ImmuneHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$16.00 ➝ $12.004/3/2025ACIUAC ImmuneHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.00 ➝ $16.003/20/2025SCPHscPharmaceuticalsMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$20.00 ➝ $12.003/20/2025SCPHscPharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$18.00 ➝ $18.003/14/2025ACIUAC ImmuneHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.00 ➝ $16.00(Data available from 6/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACIUAC Immune$28.30M6.83N/AN/A$2.12 per share0.91AVTEAerovate TherapeuticsN/AN/AN/AN/A$3.96 per shareN/ASCPHscPharmaceuticals$41.98M4.99N/AN/A$1.04 per share3.81SGTXSigilon Therapeutics$12.94M4.36N/AN/A$15.68 per share1.43Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACIUAC Immune-$60.41M-$0.58N/AN/AN/AN/A-28.26%-18.98%8/5/2025 (Estimated)AVTEAerovate Therapeutics-$75.52M-$1.70N/AN/AN/AN/A-90.19%-77.47%8/11/2025 (Estimated)SCPHscPharmaceuticals-$54.81M-$1.91N/AN/AN/A-264.60%-244.93%-68.56%8/13/2025 (Estimated)SGTXSigilon Therapeutics-$43.56M-$12.23N/AN/AN/A-171.29%-83.07%-38.17%N/ALatest SGTX, SCPH, AVTE, and ACIU EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025SCPHscPharmaceuticals-$0.28-$0.34-$0.06-$0.37$11.63 million$11.75 million4/30/2025Q1 2025ACIUAC Immune-$0.22-$0.21+$0.01-$0.21$1.99 million$1.12 million4/25/2025Q4 2024AVTEAerovate Therapeutics-$10.50-$3.15+$7.35-$0.09N/AN/A3/27/2025Q4 2024AVTEAerovate Therapeutics-$6.65-$6.65N/A-$0.19N/AN/A3/19/2025Q4 2024SCPHscPharmaceuticals-$0.40-$0.35+$0.05-$0.35$12.08 million$12.15 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACIUAC ImmuneN/AN/AN/AN/AN/AAVTEAerovate TherapeuticsN/AN/AN/AN/AN/ASCPHscPharmaceuticalsN/AN/AN/AN/AN/ASGTXSigilon TherapeuticsN/AN/AN/AN/AN/ALatest SGTX, SCPH, AVTE, and ACIU DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date4/9/2025AVTEAerovate Therapeutics$84.004/29/20254/25/20254/28/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACIUAC ImmuneN/A1.861.86AVTEAerovate TherapeuticsN/A8.788.78SCPHscPharmaceuticals1.668.086.89SGTXSigilon TherapeuticsN/A1.781.78Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACIUAC Immune51.36%AVTEAerovate TherapeuticsN/ASCPHscPharmaceuticals89.52%SGTXSigilon TherapeuticsN/AInsider OwnershipCompanyInsider OwnershipACIUAC Immune4.60%AVTEAerovate Therapeutics24.90%SCPHscPharmaceuticals4.78%SGTXSigilon Therapeutics6.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACIUAC Immune140100.41 million94.39 millionOptionableAVTEAerovate Therapeutics2028.99 million21.69 millionOptionableSCPHscPharmaceuticals3052.79 million47.28 millionOptionableSGTXSigilon Therapeutics622.51 million2.35 millionNot OptionableSGTX, SCPH, AVTE, and ACIU HeadlinesRecent News About These CompaniesRegenxbio expands MPS I gene therapy trial after first look at dataAugust 29, 2024 | pharmaphorum.comLilly & Co Eli's Net WorthMay 1, 2024 | benzinga.comMCRB Seres Therapeutics, Inc.April 14, 2024 | seekingalpha.comBeam Therapeutics Inc.October 22, 2023 | wsj.comEli Lilly Concludes Acquisition Of Sigilon TherapeuticsAugust 14, 2023 | markets.businessinsider.comLilly Completes Acquisition of Sigilon TherapeuticsAugust 14, 2023 | finance.yahoo.comSGTX - Sigilon Therapeutics, Inc.August 1, 2023 | finance.yahoo.comInside Eli Lilly's Strategic Investment In Sigilon: An Opportunity OverlookedJuly 31, 2023 | msn.comSIGILON THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sigilon ...July 21, 2023 | businesswire.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates WMC, SGTX, AJX, IMNMJuly 18, 2023 | markets.businessinsider.comCanaccord Genuity Maintains Sigilon Therapeutics (SGTX) Buy RecommendationJuly 6, 2023 | msn.comSigilon Therapeutics (SGTX) Price Target Decreased by 6.27% to 48.28July 6, 2023 | msn.com5 big deal reports: Overstock snags Bed Bath & Beyond IP; Visa pays $1B for PismoJuly 3, 2023 | msn.comShares of Cambridge biotech Sigilon soar after company OKs Eli Lilly buyoutJune 30, 2023 | wickedlocal.comLilly of the valley provides big bounce-back for Sigilon via T1D takeoverJune 30, 2023 | bioworld.comSHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Sigilon Therapeutics, Inc. BuyoutJune 29, 2023 | benzinga.comEli Lilly to buy Sigilon Therapeutics on a massive premiumJune 29, 2023 | invezz.comModerna Billionaire Set to Score 3,000% Gain on Tiny BiotechJune 29, 2023 | finance.yahoo.comEli Lilly and Company: Lilly to Acquire Sigilon TherapeuticsJune 29, 2023 | finanznachrichten.deHealth Care Company Eli Lilly Announces Acquisition of Sigilon TherapeuticsJune 29, 2023 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSGTX, SCPH, AVTE, and ACIU Company DescriptionsAC Immune NASDAQ:ACIU$1.92 -0.15 (-7.00%) As of 02:51 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical studies trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as completed Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that is in Phase Ib/2a clinical study; and Tau- positron emission tomography (PET) imaging tracer, which is in Phase II clinical study. In addition, the company is researching and developing small molecule Tau aggregation inhibitors for AD and NeuroOrphan indications. Further, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. AC Immune SA has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli Lilly and Company; and WuXi Biologics. The company was incorporated in 2003 and is headquartered in Lausanne, Switzerland.Aerovate Therapeutics NASDAQ:AVTE$7.03 -0.03 (-0.42%) As of 06/11/2025Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.scPharmaceuticals NASDAQ:SCPH$3.96 -0.04 (-0.88%) As of 02:51 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX. The company's product pipeline also includes SCP-111 (furosemide injection), an investigational pH neutral aqueous furosemide formulation that is being developed for subcutaneous administration outside of the hospital setting, including patient self-administration in the home; and SCP-111 Autoinjector, an investigational single-entity, drug-device combination product candidate consisting of a prefilled syringe containing SCP-111, preloaded into a commercially available, fixed single dose, disposable, two step mechanical autoinjector. It has a collaboration agreement with West Pharmaceutical Services, Inc. The company was incorporated in 2013 and is headquartered in Burlington, Massachusetts.Sigilon Therapeutics NASDAQ:SGTXSigilon Therapeutics, Inc., a preclinical stage biotechnology company, develops functional cures for patients with acute and chronic diseases. Its lead product candidate is SIG-002 to replace islet cells for the treatment of type 1 diabetes; and SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate to severe Hemophilia A. The company is also developing SIG-205, SIG-218, SIG-220, and SIG-005, which are to treat the non-neurological manifestations of mucopolysaccharidosis type 1; and SIG-207 is to treat of Fabry disease. Sigilon Therapeutics, Inc. has a research collaboration and license agreement with Eli Lilly and Company for the development and commercialization of SLTx product candidates for the treatment of Type 1 Diabetes. The company was formerly known as Sigilon, Inc. and changed its name to Sigilon Therapeutics, Inc. in June 2017. Sigilon Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Super Micro Computer Stock: Two Levels Smart Money Is Watching Intel's Price Spikes: Noise, or the First Notes of a Turnaround? IBM Up 10 Days in a Row: What’s Driving the Winning Streak? SoFi Stock’s Next Test: Can It Justify Its Premium Valuation? Ignore the Noise—Samsara Stock Is Still a Strong Buy Fastenal Stock After Split: Poised for 5 More Years of Gains Analysts Love Lovesac, But Investors Should Be Cautious Oracle’s Cloud Boom Is Just Getting Started Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
